Skip to main content

Advertisement

Table 1 Characteristics of PDAC patients at baseline and after the chemotherapy

From: Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Stage(s) Classification n Survival (month) (mean ± SD) CA 19-9 (units/ml) (median (range))
Baseline After chemotherapy
III Good-responder 11 23.5 ± 4.9 179.5 (85.7, 371.2) 25.6 (9.7, 148.2)
  Limited-responder 8 7.3 ± 3.2 447.4 (50.4, 17,089.3) 517.3 (19.8, 1388.5)
IV Good-responder 15 20.1 ± 8.1 1116.8 (112.3, 5229.2) 250.1 (13.3, 1851.8.4)
  Limited-responder 18 6.7 ± 3.8 5532.8 (426.0, 64,178.0) 4642.0 (195.7, 88,904.1)
III and IV Good-responder 26 21.6 ± 7.0 395.9 (67.1, 4451.9) 125.3 (9.0, 795.0)
  Limited-responder 26 6.9 ± 3.5 3164.5 (80.2, 51,831.1) 1123.9 (26.0, 55,992.8)